Company: NKLR
Filing Date: 2025-12-16
Form Type: 424B3
Source: 0001213900-25-121900
Chunk: 38

Company: Terra Innovatum Global N.V.
Filing Date: 2025-12-16
Form: 424B3
Chunk 38
---
 finalize
development of and commercialize SOLO and related services, and we may not be able to do so on our anticipated timetable, if at all.
We expect our expenses and capital expenditures to increase in connection with our ongoing activities, including developing and advancing
SOLO and other products and services, obtaining the Construction Permit and Operating Licensing Approval from NRC within the target timeline
for CPA and OLA approval for SOLO design and completing our manufacturing preparation and trials. In addition, we expect to incur additional
costs associated with operating as a public company. Certain costs are not reasonably estimable at this time and we may require additional
funding and our projections anticipate certain customer-sourced income that is not guaranteed.

We may also seek to
raise capital through private or public equity or debt financings or through other sources of financing. Adequate additional funding
may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact
on our financial condition and our ability to pursue our business strategies. If we raise additional funds by issuing equity securities,
our shareholders will experience dilution. If we raise additional capital through debt financing, we may be subject to covenants that
restrict our operations including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our securities,
make certain investments, and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity
that we raise may contain terms that are not favorable to us or our stockholders and members. If the needed financing is not available,
or if the terms of financing are less desirable than we expect, we may be required to delay, scale back or terminate some or all of our
research and development programs.

Subsequent to the balance sheet date, we completed
the Merger on October 9, 2025 (see “Business Combination and Public Listing” below) and converted $5,690,000 in Bridge
Loans into equity and warrants. Management therefore believes that existing cash will be sufficient to meet the Company’s working
capital and capital expenditure requirements for at least the next 12 months.

We rely heavily on our intellectual property portfolio. Our ability to protect our patents and other intellectual property rights may be challenged and is not guaranteed. If we are unable to protect our intellectual property rights, our business and competitive position may be harmed.

We may not be able
to prevent unauthorized use of our intellectual property, which could harm our business and competitive position